SEARCH

SEARCH BY CITATION

References

  • Arthur, D.C., Berger, R., Golomb, H.M., Swansbury, G.J., Reeves, B.R., Alimena, G., Van den Berghe, H., Bloomfield, C.D., De La Chapelle, A., Dewald, G.W., Garson, O.M., Hagemeijer, A., Kaneko, Y., Mitelman, F., Pierre, R.V., Ruutu, T., Sakurai, M., Lawler, S.D. & Rowley, J.D. (1989) The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genetics and Cytogenetics, 40, 203216.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology, 33, 451458.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Annals of Internal Medicine, 103, 620625.
  • Berger, R., Bernheim, A., Ochoa Noguera, M.E., Daniel, M.T., Valensi, F., Sigaux, F., Flandrin, G. & Boiron, M. (1987) Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genetics and Cytogenetics, 28, 293299.
  • Bloomfield, C.D. (1992) Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia, 6, 6567.
  • Bloomfield, C.D., Herzig, G.P. & Caligiuri, M.A. (1997) Introduction: acute leukemia: recent advances. Seminars in Oncology, 24, 12.
  • Bloomfield, C.D., Lawrence, D., Byrd, J.C., Carroll, A.J., Pettenati, M.J., Tantravahi, R., Patil, S.R., Davey, F.R., Berg, D.T., Schiffer, C.A., Arthur, D.C. & Mayer, R.J. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research, 58, 41734179.
  • Büchner, T., Urbanitz, D., Hiddemann, W., Ruhl, H., Ludwig, W.D., Fischer, J., Aul, H.C., Vaupel, H.A., Kuse, R., Zeile, G., Nowrousian, M.R., König, H.J., Walter, M., Wendt, F.C., Sodomann, H., Hossfeld, D.K., Von Paleske, A., Löffler, H., Gassmann, W., Hellriegel, K.-P., Fülle, H.H., Lunscken, B., Emmerich, B., Pralle, H., Von Pees, H.W., Pfreundschuh, M., Bartels, H., Koeppen, K.-M., Schwerdtfeger, R., Donhuijsen-Ant, R., Mainzer, K., Bonfert, B., Köppler, H., Zurborn, K.-H., Ranft, K., Thiel, E. & Heinecke, A. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. Journal of Clinical Oncology, 3, 15831589.
  • Büchner, T., Hiddemann, W., Löffler, G., Gassmann, W., Maschmeyer, G., Heit, W., Hossfeld, D., Weh, H., Ludwig, W.D., Thiel, E., Nowrousian, M.R., Aul, C., Lengfelder, E., Lathan, B., Mainzer, K., Urbanitz, D., Emmerich, B., Middelhoff, G., Donhuijsen-Ant, R., Hellriegel, K.-P. & Heinecke, A. (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. Seminars in Hematology, 28, 7679.
  • Büchner, T., Hiddemann, W., Wörmann, B., Löffler, H., Gassmann, W., Haferlach, T., Fonatsch, C., Hossfeld, D., Maschmeyer, G., Lengfelder, E., Aul, C., Heyll, A., Ludwig, W.-D., Sauerland, M.-C. & Heinecke, A. (1997a) Therapeutic outcome in AML is mainly determined by cytogenetics, LDH in serum, early response and, in poor risk subgroup, by intensified induction treatment. Blood, 90, 504a.
  • Büchner, T., Hiddemann, W., Wörmann, B., Zühlsdorf, M., Rottmann, R., Innig, G., Maschmeier, G., Ludwig, W.D., Sauerland, M.C. & Heinecke, A. (1997b) Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Seminars in Oncology, 24, 124131.
  • Cripe, L.D. (1997) Adult acute leukemia. Current Problems in Cancer, 21, 164.
  • Dastugue, N., Payen, C., Lafage Pochitaloff, M., Bernard, P., Leroux, D., Huguet Rigal, F., Stoppa, A.M., Marit, G., Molina, L., Michallet, M., Maraninchi, D., Attal, M. & Reiffers, J. (1995) Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia, 9, 14911498.
  • Fenaux, P., Preudhomme, C., Lai, J.L., Morel, P., Beuscart, R. & Bauters, F. (1989) Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. British Journal of Haematology, 73, 6167.
  • Ferrant, A., Doyen, C., Delannoy, A., Straetmans, N., Martiat, P., Mineur, P., Bosly, A., Van den Berghe, H. & Michaux, J.L. (1995) Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplantation, 15, 685690.
  • Ferrant, A., Labopin, M., Frassoni, F., Prentice, H.G., Cahn, J.Y., Blaise, D., Reiffers, J., Visani, G., Sanz, M.A., Boogaerts, M.A., Löwenberg, B. & Gorin, N.C. (1997) Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Blood, 90, 29312938.
  • Fonatsch, C., Gudat, H., Lengfelder, E., Wandt, H., Silling-Engelhardt, G., Ludwig, W.-D., Thiel, E., Freund, M., Bodenstein, H., Schwieder, G., Grüneisen, A., Aul, C., Schnittger, S., Rieder, H., Haase, D. & Hild, F. (1994) Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia, 8, 13181326.
  • Gale, R.P., Horowitz, M.M., Weiner, R.S., Ash, R.C., Atkinson, K., Babu, R., Dicke, K.A., Klein, J.P., Löwenberg, B., Reiffers, J., Rimm, A.A., Rowlings, P.A., Sandberg, A.A., Sobocinski, K.A., Veum-Stone, J. & Bortin, M.M. (1995) Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplantation, 16, 203208.
  • Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R.F., Burnett, A.K. & Goldstone, A.H. on behalf of the Medical Research Council Adult and Children's Leukemia Working Parties (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood, 92, 23222333.
  • Groupe Francais de Cytogenetique Hematologique (GFCH) (1994) Acute leukemia treated with intensive chemotherapy in patients with a history of previous chemo- and/or radiotherapy: prognostic significance of karyotype and preceding myelodysplastic syndrome. Leukemia, 8, 8791.
  • Guerci, A., Merlin, J.L., Missoum, N., Feldmann, L., Marchal, S., Witz, F., Rose, C. & Guerci, O. (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 85, 21472153.
  • Haferlach, T. (1996) More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity? Leukemia, 10, S5S9.
  • Hiddemann, W., Kreutzmann, H., Straif, K., Ludwig, W.D., Mertelsmann, R., Donhuijsen Ant, R., Lengfelder, E., Arlin, Z. & Büchner, T. (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood, 69, 744749.
  • Hiddemann, W., Fonatsch, C., Wörmann, B., Heinecke, A., Sauerland, M.-C., Scharnhorst, S. & Büchner, T. (1995) Cytogenetic subgroups of AML and outcome from high dose versus conventional dose ARA-C as part of double induction. Blood, 86, 267a.
  • Hiddemann, W., Kern, W., Schoch, C., Fonatsch, C., Heinecke, A., Wörmann, B. & Büchner, T. (1999) Management of acute myeloid leukemia in elderly patients. Journal of Clinical Oncology, 17, 35693576.
  • ISCN (1995) Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature (ed. by F.Mitelman). S. Karger, Basel.
  • Jahns-Streubel, G., Haase, D., Schoch, C., Wörmann, B., Büchner, T., Fonatsch, C. & Hiddemann, W. (1996) Cytogenetic subgroups of acute myeloid leukemia (AML) differ significantly in proliferative activity, cytokine production and sensitivity to GM-CSF stimulation. Blood, 88, 560a.
  • Jahns-Streubel, G., Reuter, C., Landwehr, U.A.D., Unterhalt, M., Schleyer, E., Wörmann, B., Büchner, T. & Hiddemann, W. (1997) Activity of thymidine kinase and of polymerase a as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood, 90, 19681976.
  • Johansson, B., Mertens, F. & Mitelman, F. (1994) Secondary chromosomal abnormalities in acute leukemias. Leukemia, 8, 953962.
  • Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistic Association, 53, 456481.
  • Keating, M., Cork, A., Broach, Y., Smith, T., Walters, R.S., McCredie, K.B., Trujillo, J. & Freireich, E.J. (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Research, 11, 119133.
  • Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. & Willman, C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 33233329.
  • Löwenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G., Verhoef, G.E.G., Vellenga, E., Wijermans, P., Berneman, Z., Dekker, A.W., Stryckmans, P., Schouten, H., Jehn, U., Muus, P., Sonneveld, P., Dardenne, M. & Zittoun, R. (1997) Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood, 90, 29522961.
  • Mrózek, K., Heinonen, K., De La Chapelle, A. & Bloomfield, C.D. (1997) Clinical significance of cytogenetics in acute myeloid leukemia. Seminars in Oncology, 24, 1731.
  • Pedersen-Bjergaard, J., Philip, P., Larsen, S.O., Jensen, G. & Byrsting, K. (1990) Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood, 76, 10831091.
  • Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, N.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. British Journal of Cancer, 35, 139.
  • Preisler, H.D., Rustum, Y., Henderson, E.S., Bjornsson, S., Creaven, P.J., Higby, D.J., Freeman. A., Gailani, S. & Naeher, C. (1979) Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood, 53, 455464.
  • Ravandi, F., Keating, M., Pierce, S. & Estey, E. (1997) Identification of a relatively favorable group within AML/MDS patients with chromosome 5 and/or 7 abnormalities. Blood, 90, 64a.
  • Stasi, R., Del Poeta, G., Masi, M., Tribalto, M., Venditti, A., Papa, G., Nicoletti, B., Vernole, P., Tedeschi, B., Delaroche, I., Mingarelli, R. & Dallapiccola, B. (1993) Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genetics and Cytogenetics, 67, 2834.
  • Swansbury, G.J., Lawler, S.D., Alimena, G., Arthur, D., Berger, R., Van den Berghe, H., Bloomfield, C.D., De La Chappelle, A., Dewald, G., Garson, O.M., Hagemeijer, A., Mitelman, F., Rowley, J.D. & Sakurai, M. (1994) Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genetics and Cytogenetics, 73, 17.
  • Terpstra, W. & Löwenberg, B. (1997) Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia, 11, 315327.
  • Warrell, Jr, R.P. (1998) Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia. International Journal of Cancer, 70, 496497.
  • Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. & Fenaux, P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 31483157.
  • Wheatley, K., Burnett, A.K., Goldstone, A.H., Hann, I.M., Stevens, R.F., Rees, J.K.H. & Gray, R.G. & MRC Adult and Childhood Leukaemia Working Parties (1996) Factors relating to the achievement of complete remission (CR) in younger patients with acute myeloid leukemia (AML) in the united kingdom medical research council (MRC) AML 10 trial. Blood, 88, 214a.
  • Willman, C.L. (1996) Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia, 10, S33S35.
  • Yunis, J.J., Brunning, R.D., Howe, R.B. & Lobell, M. (1984) High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia. New England Journal of Medicine, 311, 812818.